RT Journal Article
SR Electronic
T1 Digital Herd Immunity and COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.15.20066720
DO 10.1101/2020.04.15.20066720
A1 Bulchandani, Vir B.
A1 Shivam, Saumya
A1 Moudgalya, Sanjay
A1 Sondhi, S. L.
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.04.15.20066720.abstract
AB A population can be immune to epidemics even if not all of its individual members are immune to the disease, just as long as sufficiently many are immune—this is the traditional notion of herd immunity. In the smartphone era a population can be immune to epidemics even if not a single one of its members is immune to the disease—a notion we propose to call “digital herd immunity”, which is similarly an emergent characteristic of the population. This immunity arises because contact-tracing protocols based on smartphone capabilities can lead to highly efficient quarantining of infected population members and thus the extinguishing of nascent epidemics. When the disease characteristics are favorable and smartphone usage is high enough, the population is in this immune phase. As usage decreases there is a novel “contact tracing” phase transition to an epidemic phase. We present and study a simple branching-process model for COVID-19 and show that digital immunity is possible regardless of the proportion of non-symptomatic transmission. We believe this is a promising strategy for dealing with COVID-19 in many countries such as India, whose challenges of scale motivated us to undertake this study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data shown in the paper is available to readers